Janssen's Tremfya (guselkumab) Receives FDA's Approval for Moderate-to-Severe Plaque Psoriasis in Adults
Shots:
- The approval is based on P-III study results assessing Tremfya (guselkumab- 100mg) vs PBO in 78 patients with moderate-to-severe plaque psoriasis
- P-III ORION study: IGA score of 0/1 or PASI 90 @16wks. (81%- 76% vs 0%-0%); IGA score of 0 @16 wk (56% vs 0%); PASI 100 response @16 wks (50% vs 0%)
- Tremfya (guselkumab-100mg- SC) is a mAb offering one-press patient-controlled injector inhibiting interleukin (IL)-23- evaluated in two P-III trials for active psoriatic arthritis & Crohn’s disease and is approved in the US- EU- Canada & Japan for moderate-to-severe plaque psoriasis in adults
Ref: Janssen | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com